Reports of T cell anergy in CML patients to specific leukemia-associated antigens have included the demonstration of an inability to raise BCR-ABL-targeting T cells from PBMCs derived from CML but not healthy volunteers [28], as well as the reduction in number of T cells specific for the CML antigen PR1 in interferon non-responding patients [29]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.